Organon & Co (OGN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Organon & Co stock $11.83, price $13.87, that is 14.7% below the price, quality 45 out of 100. Rating: overvalued. Calculated from audited financials with 19 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range $5.68 – $32.84 · fair‑value band $6.78 – $20.75 · the $13.87 price screens above the $11.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Organon & Co in your weekly email
Every Wednesday you see whether Organon & Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Show moreShow less
The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist.
The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands.
In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.
The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Stock analysis
Organon & Co (OGN) currently trades at $13.87, while our model-based Fair Value estimate is $11.83, 15% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $32.29 per share, and 8 of the 19 models we run sit above the $13.87 price.
Bear case: the Dividend Discount group reads lowest at $2.94, and 11 of the 19 models stay below the price. Data coverage for this calculation is high.
Scenario range: $6.78 (bear) to $20.75 (bull), the price of $13.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Organon & Co reported revenue of $6.2B in FY2025 versus $6.3B in FY2021, a compound −0.4%/yr. Reported net income was $187M in FY2025, compounding −39.0%/yr from FY2021.
Key figures
Market cap $3.8B Mid · P/E ratio 17.8 · P/S ratio 0.62 · EPS (TTM) $0.7800 · Dividend yield 2.5% · Net margin 3.5% · Return on equity 20.3% · Return on assets (EBIT) 13.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 144% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −15%, OGN screens richer than that median.
Fair Value models
Bear$6.78Fair Value $11.83Bull$20.75
Price $13.87 · Downside -14.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3761 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $200,307 and none bought.
SaleJuliana Papa DrinaneHead of Mfg & Supply14,761 shares at $13.57$200,307Aug 5, 2026
BuyLynette HolzbaurSVP and Corporate Controller26,448 shares at $13.35$353,086May 6, 2026
SaleLynette HolzbaurSVP and Corporate Controller26,448 shares at $13.35$353,086May 6, 2026
BuyCarrie Smith CoxExecutive Chair, Director65,400 shares at $7.67$501,618Nov 12, 2025
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.3%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−24.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−26.5%
Dividend (yield on the price)2.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.44% → 21%
⚠ Revenue per share shrinking 7.3%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.0% a year for the price and −0.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (88 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Moderate business quality with a steady portfolio in contraception and biosimilars as main strength, yet leverage pressure and thin differentiation remain the central weaknesses.
Main risk: Prioritising balance sheet repair risks constraining investments needed to capture growth in women's health products such as MIUDELLA and VTAMA.
Organon is shifting emphasis toward repairing its balance sheet and stabilizing EBITDA through asset sales and a broader but steadier portfolio in contraception and biosimilars. This comes as growth acceleration in women's health products like the MIUDELLA IUD extension and VTAMA real-world data takes a back seat. Our models currently view the stock as overvalued. Will balance sheet repair lay a stronger base for expansion or simply constrain the investments needed to capture those opportunities?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Bottom 25%
Fair Value upside−14.7% · Below median
Profitability
Return on equity (12 months)20.3% · Above median
Return on assets1.5% · Bottom 25%
Net margin (12 months)3.5% · Below median
Operating margin (12 months)23.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−1.7% · Bottom 25%
Dividend yield (12 months)2.5% · Above median
Balance sheet
Debt / equity11.47× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)17.8× · Cheaper than median
P/B4.99× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Organon & Co Fair Value". https://www.fairvalue-calculator.com/stock/OGN
Frequently asked questions
Is Organon & Co (OGN) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $11.83 versus a price of $13.87, about 15% lower (overvalued).
What is the fair value of OGN?
Our model-based fair value for Organon & Co is $11.83 (as of Nov 3, 2026), built from audited fundamentals. The current price: $13.87.
What is the quality score of OGN?
Organon & Co has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Organon & Co (OGN)?
Our model-based price target is the fair value of $11.83 (as of Nov 3, 2026) from 19 valuation models. Cautious scenario $6.78, optimistic scenario $20.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Organon & Co stock forecast for 2026?
Our models put fair value at $11.83, about 15% lower versus a price of $13.87 (overvalued). Cautious scenario $6.78, optimistic scenario $20.75. The calculation is refreshed regularly with new filings.
What is the revenue of Organon & Co (OGN)?
Organon & Co reported trailing-twelve-month revenue of about $6.1B (latest available figure, as of Nov 3, 2026).
Does Organon & Co pay a dividend?
Organon & Co currently shows a dividend yield of 2.45% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Organon & Co (OGN) and when is the ex-dividend date?
Organon & Co pays a dividend of $0.34 per share a year, a dividend yield of 2.5%. The next ex-dividend date is Nov 9, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 16.8% of earnings (on adjusted earnings, reported 43.6%). Free cash flow covers the dividend 6.03 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Organon & Co (OGN)?
For today's price to be fair in a discounted-cash-flow model, Organon & Co would have to grow free cash flow by +14.6 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.0 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of OGN use?
Our models discount Organon & Co at 11.1 %: a base by market capitalisation (mid), damped by beta 1.54, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Organon & Co that is +14.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Organon & Co (OGN) delivered so far?
Over the past 5 years revenue at Organon & Co grew -1.0 % a year. The price currently implies free-cash-flow growth of +14.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Organon & Co (OGN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Organon & Co (+14.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Organon & Co (OGN)?
The free-cash-flow yield on the price is 14.34 %: that much free cash flow Organon & Co produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Organon & Co (OGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Organon & Co it is $11.83 per share (as of Nov 3, 2026), against a price of $13.87. It is the blended result of 19 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Organon & Co stock overvalued or undervalued in 2026?
As of Nov 3, 2026, OGN trades above its calculated fair value: price $13.87, fair value $11.83, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OGN?
No. The price is what the market pays today ($13.87); the fair value is what the company's own numbers justify ($11.83). For Organon & Co the two are $2.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Organon & Co worth?
The market values Organon & Co at about $3.8B (market capitalisation, as of Nov 3, 2026). Per share that is $13.87; our models calculate a fair value of $11.83 per share.
What do the bullish and bearish scenarios say about OGN?
Our models span a range for Organon & Co: cautious scenario $6.78, base $11.83, optimistic $20.75 per share (as of Nov 3, 2026, price $13.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OGN?
Organon & Co trades at a price-to-earnings ratio of 17.8 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $11.83 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 7.4 (reported for FY2025: 19.3). Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings, 4 of the years ex one-offs: 5.7. Other multiples: P/B 5.0, P/S 0.6, EV/EBITDA 7.5.
How solid is the balance sheet of Organon & Co (OGN)?
Balance-sheet figures for Organon & Co (as of Nov 3, 2026): return on equity 20.3%, debt of 11.47 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is OGN from its 52-week high?
Organon & Co trades at $13.87, at its 52-week high of $13.87 and 144% above the low of $5.68 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $11.83 is for.
Which stocks are comparable to Organon & Co?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Organon & Co stock attractive at the current price?
The data as of Nov 3, 2026: price $13.87, calculated fair value $11.83 (−15%), Quality Score 45/100, from 19 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OGN calculated?
We run Organon & Co through 19 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $11.83 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Organon & Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Organon & Co (OGN)?
The closing price on Nov 6, 2026 was $13.87. Our model-based fair value is $11.83, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Organon & Co right now?
The model range is unusually wide ($6.78 to $20.75). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Organon & Co
How large is the market capitalisation of Organon & Co (OGN)?
The market capitalisation of Organon & Co is $3.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Organon & Co (OGN)?
The price-to-sales ratio of Organon & Co is 0.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Organon & Co (OGN)?
Earnings per share at Organon & Co are $0.7800 (price ÷ EPS = P/E 17.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Organon & Co (OGN)?
The dividend yield of Organon & Co is 2.5% (payout 16.8%, on adjusted earnings, reported 43.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Organon & Co (OGN)?
The net margin of Organon & Co is 3.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Organon & Co (OGN)?
The return on equity (ROE) of Organon & Co is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Organon & Co (OGN)?
On an EBIT basis the return on assets of Organon & Co is 13.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Organon & Co (OGN)?
The operating margin of Organon & Co is 23.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Organon & Co (OGN)?
Revenue at Organon & Co is growing −1.7% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Organon & Co (OGN)?
Earnings per share at Organon & Co are growing −1.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Organon & Co (OGN) carry?
The net debt of Organon & Co is $8.2B (fiscal year 2025, ≈ 15.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Organon & Co in the live analysis
One click puts Organon & Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026